UncategorizedNeurona Therapeutics receives EMA PRIME designation for NRTX-1001 in drug-resistant focal epilepsy – Longevity.Technology Empower Meds / November 6, 2025
UncategorizedJupiter Neurosciences receives FDA clearance to begin Phase 2a trial of JOTROL in Parkinson’s disease – Longevity.Technology Empower Meds / November 6, 2025
UncategorizedPretzel Therapeutics presents POLRMT preclinical data at ObesityWeek 2025 – Longevity.Technology Empower Meds / November 5, 2025
UncategorizedSky Labs secures investment from Omron subsidiary OMRON Ventures – Longevity.Technology Empower Meds / November 5, 2025
UncategorizedSerina Therapeutics faces clinical hold on its SER-252 Parkinson’s program – Longevity.Technology Empower Meds / November 5, 2025
UncategorizedOmada Health to present real-world GLP-1 insights at ObesityWeek 2025 – Longevity.Technology Empower Meds / November 5, 2025
UncategorizedTimeline continues building expanded longevity product pipeline – Longevity.Technology Empower Meds / November 5, 2025
UncategorizedArena BioWorks shuts down, citing ‘biotech macro conditions’ Empower Meds / November 5, 2025
